Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
RELATIVITY-1093
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- NCT06561386 ↗
- Recruiting
- Bristol-Myers Squibb
- Focused
We haven't built an HCP commentary report on RELATIVITY-1093 (nivolumab plus relatlimab) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RELATIVITY-1093 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 3 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Nivolumab; Relatlimab; Pembrolizumab; Carboplatin; Pemetrexed; Cisplatin
- Arms
- Arm A · Experimental
- Arm B · Active comparator
- Enrollment
- 1,000 (estimated)
- Primary outcomes
- Overall survival (OS) in randomized participants with PD-L1 1% to 49%
- Sponsor
- Bristol-Myers Squibb
- Start
- Oct 7, 2024
- Primary completion
- Jul 30, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06561386 · updated Oct 23, 2026